TWC
STIM icon

TD Waterhouse Canada’s Neuronetics STIM Stock Holding History

TD Waterhouse Canada’s Portfolio STIM Stock Details STIM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$80 Hold
59
– – ﹤0.01% 2329
2026
Q1 		$87 Buy
+59
New +$94 ﹤0.01% 2227

Other funds holding STIM

MAM
Madryn Asset Management New York $36.9M AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
WC
Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return
FCM
FourWorld Capital Management New York $110M AUM 44.07% 1-Year Est. Return
LG
Lane Generational Dover, Massachusetts $114M AUM 43.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
AI
AdvisorShares Investments Bethesda, Maryland $828M AUM 37.72% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $928M AUM 596.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

TD Waterhouse Canada's STIM Position: Q2 2026 in Review

TD Waterhouse Canada held its Neuronetics (STIM) position steady in Q2 2026 at 59 shares worth $80. The position accounts for ﹤0.01% of the portfolio, ranked #2329.

TD Waterhouse Canada first reported a position in STIM in Q1 2026 and has held it in 2 quarters since. The position peaked at $87 in Q1 2026. 86 funds tracked by Wall St. Rank hold STIM as of Q2 2026.

  • TD Waterhouse Canada held 59 shares of Neuronetics worth $80 as of Q2 2026.
  • TD Waterhouse Canada left its Neuronetics share count unchanged in Q2 2026.
  • Neuronetics made up ﹤0.01% of TD Waterhouse Canada's portfolio in Q2 2026, its #2329 holding.
  • TD Waterhouse Canada first reported a position in Neuronetics in Q1 2026 and has held it in 2 quarters since.
  • TD Waterhouse Canada's Neuronetics position peaked at $87 in Q1 2026.
  • 86 funds tracked by Wall St. Rank held Neuronetics as of Q2 2026.

Based on TD Waterhouse Canada's 13F filing for Q2 2026, filed 27 Jul 2026.